GlassScriptPhysician profile
Lauren Eckert Ploch
NPI 1114151800
$3,413.25
in general payments reported to CMS, 2019-2025
24 companies · $174 in 2025
The $174 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $694 · 2020: $205 · 2021: $502 · 2022: $234 · 2023: $889 · 2024: $715 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,572 · Education: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,572.04 |
| Education | $205.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $542.53 | 2019-2024 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $541.11 | 2019-2025 | |
| Pfizer INC. | $349.33 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $290.37 | 2019-2025 | |
| Amgen INC. | $258.99 | 2020-2025 | Otezla |
| Galderma Laboratories, L.P. | $186.19 | 2021-2025 | Aklief, Twyneo, Epsolay |
| Sun Pharmaceutical Industries INC. | $185.25 | 2019-2024 | Ilumya |
| Leo Pharma INC. | $160.00 | 2019-2025 | Adbry |
| Genzyme Corporation | $158.09 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $142.17 | 2019-2024 | Libtayo, Dupixent |
| Merck Sharp & Dohme LLC | $106.45 | 2022-2024 | Keytruda |
| Lilly USA, LLC | $95.55 | 2019-2023 | Taltz, Olumiant |
| Celgene Corporation | $68.18 | 2019 | |
| Ucb, INC. | $64.32 | 2023-2024 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $56.77 | 2021-2023 | Arazlo, Jublia, Duobrii |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $43.80 | 2023-2024 | Zoryve |
| Allergan, INC. | $33.82 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.95 | 2024 | Spevigo |
| Dermavant Sciences, INC. | $21.97 | 2024 | Vtama |
| Organogenesis INC. | $20.32 | 2024 | Novachor |
| Genentech, INC. | $19.45 | 2023 | Erivedge |
| Paratek Pharmaceuticals, INC. | $19.10 | 2024 | Nuzyra |
| Almirall LLC | $17.75 | 2021 | |
| Prugen, INC. Pharmaceuticals | $8.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Ploch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.